We evaluated the risk factors for infection of 367 consecutive myeloma patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT). Examination of bone marrow iron stores (BMIS) prior to ASCT was used to evaluate body iron stores. Other variables included age, sex, active smoking, myeloma remission status, severity of mucositis and duration of severe neutropenia post-ASCT (o100 absolute neutrophils counts (ANC)/ll). Median age was 56 years; 61% of patients were males. 140 episodes of severe infections occurred in 116 patients, including bacteremia (73), pneumonia (40), severe colitis (25) and bacteremia with septic shock (two). The infection incidence per 1000 days at risk was 45.2. Pre-ASCT risk factors for severe infection by univariate analysis were increased BMIS (OR ¼ 2.686; 95% CI 1.707-4.226; Po0.0001), smoking (OR ¼ 1.565; 95% CI 1.005-2.437; P ¼ 0.0474) and male gender (OR ¼ 1.624; 95% CI 1.019-2.589; P ¼ 0.0414). Increased BMIS (OR ¼ 2.716; 95% CI 1.720-4.287; Po0.0001) and smoking (OR ¼ 1.714; 95% CI 1.081-2.718; P ¼ 0.022) remained significant by multivariate analysis. Duration of ANC o100 l/l (OR ¼ 1.129; 95% CI 1.039-1.226; P ¼ 0.0069 and OR ¼ 1.127; 95% CI 1.038-1.224; P ¼ 0.0045 by both univariate and multivariate analysis, respectively) was the only post-ASCT risk factor for infection. Increased pre-transplant BMIS and smoking are significant predictors of severe infection after myeloablative chemotherapy followed by ASCT in myeloma patients.
Introduction
High-dose melphalan with autologous peripheral blood stem transplantation (MEL-ASCT) improves the outcome of patients with multiple myeloma (MM) and has now become standard therapy for patients under 65 years of age. 1, 2 This procedure may, however, be associated with serious infections, particularly during the pre-engraftment period. 3 A few studies have evaluated early infections after ASCT and identified several risk factors including the number of stem cells infused, 4 time to platelet engraftment, 5 presence of indwelling central venous catheter, contamination of stem cells and therapy-related mucosal damage. 6, 7 Duration of neutropenia was shown to be an important risk factor in some, 8, 9 but not all studies. 5, 10, 11 These studies were limited, however, by small sample size, heterogeneity of the population studied and omission from analysis of potentially important risk factors such as iron overload and a history of smoking.
We sought to determine the risk factors for early severe infections following MEL-ASCT in a large and homogeneous population of myeloma patients undergoing similar therapies (induction, stem cell mobilization, ASCT and supportive care standards).
Materials and methods
This study was conducted at the Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, and was approved by the Institutional Review Board.
From October 1998 to December 2002, 382 consecutive adult patients with newly diagnosed MM were enrolled in our study UARK 98-026 (Total Therapy II) protocol which consisted of four phases: All patients were initially randomized to receive thalidomide or no thalidomide throughout therapy. For those included in the thalidomide arm, the drug was withheld 1 week prior to MEL-ASCT and resumed once the platelet count reached 75 000/ml. 2 All patients had a central venous catheter in place during the study period and received antimicrobial prophylaxis consisting of acyclovir, fluconazole and a fluoroquinolone (levofloxacin, or gatifloxacin) until recovery from neutropenia (absolute neutrophil count (ANC) X1000 cells/ml).
Demographic and clinical data of these patients were retrospectively reviewed to determine the presence, type and risk factors for early (days 0-60) severe infections following the first MEL-ASCT.
Severe infection referred to any infectious episode (as defined by the Centers for Disease Control and Prevention 12 ) requiring IV antibiotics, oxygen supplementation, pressors and/or intubation. Severe infections included septic shock, bacteremia, pneumonia and infectious colitis.
Neutropenia was defined as mild, moderate and severe in the presence of ANC of o1000 cells/ml, o500 cells/ml and o100 cells/ml, respectively.
Mucositis was assessed by research nurses trained in the evaluation of mucositis. They reviewed and scored the mucositis data including stomatitis, dysphagia-esophagitis and colitis and graded them as Grade 0-4 as defined on the Common Toxicity Criteria from the National Cancer Institute CTC Version 2.0, April 30, 1999 (http://ctep. cancer.gov/forms/CTCv20_4-30-992.pdf).
Variables were classified as Pre-ASCT if they were measured immediately prior to the infusion of MEL. Pre-ASCT variables consisted of demographics (age, gender, weight, body surface area, body mass index), active smoking (regardless of number of pack years), history of deep venous thrombosis, bone marrow cytogenetic abnormalities, allocation to thalidomide therapy or control, response to induction (prior to first MEL-ASCT), number of CD34 þ cells/kg collected and infused. Pre-ASCT laboratory studies included white blood cells, absolute neutrophil counts (ANC), platelet count, red blood cells, hematocrit, serum creatinine, calculated creatinine clearance, C-reactive protein, serum levels of glucose and albumin, liver function tests including lactic dehydrogenase (LDH), arterial blood gases and cytomegalovirus serostatus; cardiac ejection fraction and pulmonary function tests. Melphalan dose in mg/kg body weight was also evaluated.
Alcoholism was an exclusion criterion for study enrollment. Hence, this risk factor could not be evaluated.
Because of the known association between increased body iron and the risk for various infections, 13 pre-ASCT bone marrow iron stores (BMIS) were also evaluated. Histological examination of the bone marrow smears was performed to determine the BMIS which was categorized as adequate, decreased or increased based on the amount of stainable iron. 14 Only patients who had a bone marrow aspirate and/or a biopsy performed within a month prior to transplant were included.
Variables were classified as Post-ASCT if they were measured during the 60 days following MEL-ASCT. Post-ASCT variables included presence and severity of oral mucositis, deep venous thrombosis, duration of neutropenia (ANCo100, o500 and o1000), hematocrit nadir, maximum values of calculated creatinine clearance, C-reactive protein, plasma glucose level and liver function tests.
Statistical analysis
All statistical analyses were performed with SAS 9.1 (SAS Institute Inc., Cary, NC, USA). Logistic regression analysis was used to predict risk factors for severe infection. Gender, cytogenetic abnormalities, allocation to thalidomide, myeloma response to induction and to ASCT and cytomegalovirus serostatus, smoking status and history of deep venous thrombosis were analyzed as categorical variables. All other clinical variables were analyzed as continuous variables. All independent variables were tested by univariate logistic regression analysis. Variables with P-value p0.25 from univariate analysis were considered candidates for fitting the best logistic regression model. In multiple logistic regression analysis, the stepwise selection method was used to identify independent risk factors and to develop a model for predicting the estimated probability of a patient developing severe infection. The level of statistical significance chosen was 0.05. The infection incidence density per 1000 patient-days at risk (days with ANCo 100/ml) was calculated by using the device-associated infection rate formula. 15 
Results
A total of 382 consecutive patients with newly diagnosed MM were evaluated. Fifteen patients were excluded from analysis because of the lack of availability of a bone marrow biopsy obtained within 1 month of MEL-ASCT, leaving a total of 367 evaluable patients. Median age was 56 years (range: 30-77 years) and 225 patients (61%) were males (Table 1) . One hundred and forty episodes of severe infections occurred in 116 patients (31.6%) and included bacteremia (73), pneumonia (40) , severe colitis (25) and septic shock (two) ( Table 2) .
The infection incidence density per 1000 days at risk (days with ANCo100) was 45.2.
Pre-ASCT risk factors for severe infection by univariate analysis were male gender, smoking and increased BMIS (Table 1) . Increased BMIS and smoking remained significant by multiple logistic regression analysis ( Table 1) . As expected, the proportion of patients with increased BMIS was significantly higher among men and postmenopausal women (X50 years of age) compared with pre-menopausal women (P ¼ 0.0004) and a trend towards a lower risk for infection among the latter population was observed (P ¼ 0.09) (Figure 1) .
We also performed a post hoc analysis for the relationship between smoking and bacteremia and pneumonia. A significant association was found between smoking and bacteremia (P ¼ 0.0296), but surprisingly, smoking did not appear to increase the risk for pneumonia (P ¼ 0.79).
The Post-ASCT risk factor that was a significant predictor of severe infection by either univariate and/or multiple analyses was the duration of severe neutropenia (ANCo100/ml) ( Table 3 ).
Discussion
Our results show that iron overload and active smoking are important pre-transplant risk factors for severe infections in MEL-ASCT myeloma patients. The duration of ANC o100/ml was the dominant risk factor during the post transplantation phase.
The availability of iron for microbial multiplication and the negative effects of excessive iron on the antimicrobial functions of neutrophils, monocytes, macrophages and natural killer cells play a central role in the pathogenesis of infection. 16, 17 Iron overload is a recognized risk factor for infection in various settings such as chronic hemodialysis, 13, 18, 19 HIV infection, 20 primary hemochromatosis [21] [22] [23] and thalassemia 24 and with various pathogens including Yersinia enterocolitica and Listeria monocytogenes, 13,16 the agents of mucormycosis, 25, 26 non-cholera vibrio species, 27 Plasmodium falciparum, 28 Mycobacterium tuberculosis,
13
Mycobacterium avium complex, 29 Candida albicans, 30 aspergillus species 31, 32 and others. Iron overload has also been suggested as a risk factor for infections in small series of patients with hematological cancer undergoing autologous and allogeneic hematopoietic transplantation. 25, 32, 33 Altes et al. 32 evaluated the relationship between liver iron stores content and invasive aspergillosis among 59 patients who died after undergoing autologous or allogenic peripheral stem cell transplant and underwent autopsy examination. Patients with increased hepatic iron (X150 mmol/g) had a 37% rate of invasive aspergillosis compared with a 12% rate for those whose hepatic-iron concentration was o150 mmol/g (P ¼ 0.012; RR 9; 95% CI: 1.6-50.3). 32 The same authors evaluated the impact of very high levels of serum ferritin (X3000 g/l) and transferrin saturation (X100%) on mortality among 25 patients who underwent autologous 15 or allogenic 10 stem cell transplantation. Most deaths were caused by infections. In this study, elevated levels of ferritin and transferrin saturation were associated with a decreased overall survival (Po0.001 and P ¼ 0.006, respectively). 33 In a matched control study of 15 allogeneic bone marrow transplant recipients, Maertens et al. 25 showed that the number of red cell transfusions and Figure 1 Distribution of bone marrow iron stores and incidence of severe infection among male and pre-and post-menopausal female patients.
Risk for infection in stem cell transplantation MH Miceli et al the mean levels of serum ferritin and transferrin saturation were significantly higher among the five patients with mucormycosis compared with the 10 matched controls (Po0.05).
The strong association between increased BMIS and risk for severe infection in our 367 consecutive myeloma patients undergoing MEL-ASCT supports the findings of these smaller studies and are in agreement with the importance of iron overload in the pathogenesis of various infections. 13, [25] [26] [27] [28] [29] [30] [31] [32] 34 We used bone marrow examination as a marker for iron stores. Although assessment of marrow iron stores is subject to significant inter-observer variability, it is widely considered as the gold standard for the diagnosis of iron deficiency.
14 In addition, the strong association between iron stores in bone marrow and in other tissues in patients with hematological cancer undergoing stem cell transplantation 25, 31 and our findings of significantly lower iron stores among premenopausal women suggest that this test can still be relied on as a good indicator of total body iron stores. Serum ferritin levels and transferrin saturation can be also used as markers for body iron stores. Unfortunately, these tests are unreliable in the presence of acute inflammation (infection, malignancy such as MM) and liver dysfunction. 35 Because bone marrow examination is routinely performed in patients with hematological cancer undergoing ASCT, marrow iron represents an inexpensive, simple and widely available method for determining tissue iron stores in this patient population.
That cigarette smoking is a risk factor for infection is not surprising as smoking causes structural changes in the respiratory tract, decreases humoral and cellular mediated immunity and has been shown to increase the risk for infection at various sites (otitis media, periodontitis, gastritis and disseminated infections) and with various pathogens including M. tuberculosis, Streptococcus Table 3 Post transplant characteristics of 367 myeloma patients undergoing high-dose melphalan and autologous transplant: univariate and multivariate logistic regression analysis Neutropenia is a known risk factor for infection in cancer patients. 37 However, the role of neutropenia as a risk factor for infection in ASCT recipients has been supported in some 8, 9 but not all studies. 5, 10, 11 These contradictory results may be due to the heterogeneous populations and therapies reported in these studies. In agreement with others, 8, 9 the duration of profound neutropenia was the most important post transplant risk factor for severe infection in our large and homogeneous population of 367 MM patients. A correlation between increased BMIS and neutropenia (depth and duration) could not be identified.
Because we focused our evaluation on a homogeneous population of newly diagnosed myeloma patients undergoing MEL single agent conditioning for ASCT, we did not assess some of the previously reported risk factors for infection such as disease type, stage and extent of prior therapy and the type of conditioning regimen. 7 A previously shown relation between older age and increased risk of infection after ASCT 5, 10, 11 was not found in our study, probably because our homogenous population consisted mainly of middle-aged adults (mean7s.d. 5579 years). We had previously shown that male gender was an independent risk factor for infection after therapy for acute leukemia. 38 In our current study, male gender was a risk factor for infection by univariate (P ¼ 0.0414; OR 1.624; 95% CI 1.019-2.589) but not multivariate analysis. This is best explained by the relationship between male gender and increased iron stores. 35 Indeed, 41% of our 225 male population had increased iron stores compared with only 29% of pre-menopausal women (P ¼ 0.1439) (Figure 1 ). Of note, iron stores status was not evaluated as a variable in our study of acute leukemia in which male gender was found to be an independent risk factor for infection. 38 These findings suggest that the protective effect of female gender is conferred by the lower body iron stores of premenopausal female subjects. 35 Similarly, the known protective effect of a high stem cell dose in myeloma patients undergoing MEL-ASCT 39 was suggested (P ¼ 0.0747 by univariate analysis) ( Table 1) . However, the fact that only 2% of our patients had a low stem cell dose (o2 Â 10 6 CD34 þ cells/kg of body weight) infused and the close inter-relationship between stem cell dose and duration of neutropenia 40 probably account for the lack of significance of stem cell dose as an independent risk factor for infection. In addition, we could not show the association between mucositis and infection suggested by others 6 perhaps as a result of the close temporal relationship between mucositis and neutropenia or because the more accurate daily mucositis scores were not measured. Analysis of area over the curve of mucositis score constitutes a more appropriate method for evaluating the role of mucositis as a risk factor. 41 Our study suffers the limitations inherent to retrospective studies including the lack of evaluation of potentially important variables such as smoking exposure (pack years), history of prior infection and others. Further research may Table 4 Risk of and strategies for the prevention of severe infections in patients undergoing high dose chemotherapy be required to better understand the role of these and other potential risk factors for infection following MEL-ASCT. In addition, our findings on the importance of increased iron stores should be confirmed using more modern methods for estimating total body iron, and should be confirmed in other populations. In the absence of inflammation, serum ferritin levels and transferrin saturation may prove more accurate than marrow examination in determining total body iron stores. Biochemical assessment of liver iron content after hepatic biopsy remains the most accurate method for determining total body iron stores.
14 However, such an invasive procedure cannot be justified and/or performed in this patient population. These difficulties have now been overcome with the introduction of magnetic resonance imaging for non-invasive detection and quantification of liver iron content. 42 It could be hypothesized that iron overload may only be a marker for a more advanced myeloma and/or poor patient condition with the latter two variables representing the true risk for increased infection. However, all our patients had newly diagnosed myeloma and had not received antimyeloma therapy prior to enrollment. In addition, the variables classically associated with a worse myeloma prognosis (cytogenetics, serum LDH and b2 microglobulin and response to antimyeloma therapy) did not differ among patients regardless of iron stores (increased vs others) and were not found to be risk factors for increased infection in the univariate analysis (data not shown).
Our findings have several important clinical and research implications. The higher risk for infection conferred by smoking and iron overload suggests that patients with these risk factors who are scheduled to undergo MEL-ASCT should be considered at higher risk for severe infection. These patients should be educated about the importance of smoking cessation 36, 43 and prevention of exposure to sources of infection. 44 In addition, these patients should be given appropriate antimicrobial prophylaxis and larger doses of CD34 þ (X5 Â 10 6 cells/kg) and should be closely followed during the period at risk. Iron chelation may be considered in patients with severe iron overload, particularly that safer and orally available agents are now available and appear very promising in their ability to reduce the risk for infection. 34 Serial therapeutic erythrocytapheresis, which removes 200-250 mg of iron with each 500 ml of blood, 45 in combination with erythropoietin 46 is yet another treatment modality for this condition.
A comprehensive risk-based strategy to reduce the infectious complications after high-dose chemotherapy based on previous publications 7 and our current work is presented in Table 4 .
We conclude that iron overload, smoking and prolonged profound neutropenia are significant predictors for severe infection after MEL-ASCT in newly diagnosed patients with MM.
